(Q38168460)

30 August 2017

Intralesional immunotherapy for melanoma (English)

1 reference

30 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301265%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Peter Hersey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301265%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

3 December 2013

1 reference

Journal of Surgical Oncology

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301265%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301265%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301265%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

320-326

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301265%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

10 June 2020

cites work

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

21 January 2018

1 reference

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

21 January 2018

1 reference

Intralesional BCG in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

21 January 2018

1 reference

GM-CSF-secreting melanoma vaccines

21 January 2018

1 reference

Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells

21 January 2018

1 reference

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma

21 January 2018

1 reference

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

21 January 2018

1 reference

21 January 2018

1 reference

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

21 January 2018

1 reference

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

21 January 2018

Oncolytic virotherapy

1 reference

Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

21 January 2018

1 reference

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

21 January 2018

1 reference

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

21 January 2018

1 reference

Local and intralesional therapy of in-transit melanoma metastases

21 January 2018

1 reference